摘要
目的观察重组人血管内皮抑制素注射液（恩度）持续微量泵给药联合化疗治疗多种晚期恶性肿瘤的有效性和安全性。方法经病理组织学或细胞学检查确诊的Ⅲ、Ⅳ期恶性肿瘤患者37例随机分为2组。实验组（n=16）：恩度注射液持续微量泵给药,剂量为135 mg,加入3个微量输液泵中持续输注（360 h）,21 d重复。对照组（n=21）：重组人血管内皮抑制素注射液常规给药,其中恩度15 mg,加入生理盐水500 mL中匀速缓慢静脉滴注,第1~14天连续给药,间歇7天重复;同时联合既往未使用的或既往治疗无交叉耐药的化疗药物,每21天为1个周期。用药1周期后评价毒性反应,2周期后评价疗效。结果实验组治疗有效率明显高于对照组（P〈0.01）;2组生活质量改善情况及毒性反应发生情况相当。结论微量输液泵持续输注恩度临床有效率高于常规给药方案,值得临床推广应用和深入观察。
Objective To observe prospectively and systematically the efficacy and safety of rh-endostatin injection（YH-16,Endostar） durative transfusion combined with the chemotherapy on kinds of advanced malignancies.Methods Endostar combined with chemotherapy were administrated to 37 malignant cases of Stage Ⅲ～Ⅳ confirmed by histopathology or cytopathology.The 37 patients were randomly divided into two groups： experimental group（n=16） treated with endostar durative transfusion combined with chemotherapy： 135 mg endostar was solved in 3 mini-transfer pump was administered by continuous infusion for 360 hours and repeated after 21 days later.Control group（n=21）,treated with endostar combined with chemotherapy,was confirmed by histopathology or cytopathology.15 mg endostar solved in 500 mL of normal saline was slow 21intravenously dropped from day 1 to day 14 and repeated 7 days later.The chemotherapy agents which were not used before or not cross-resistant to pre-chemotherapeutic agents were selected to be given simultaneously.The regimen was repeated every 21days.The efficacy was evaluated strictly after 2 cycles according to RECIST criteria,and quality of life（QOL） was evaluated according to Karnofsky scores.Results Experimental groups treatment efficiency was obviously higher than that in the control group（P0.01）;life quality improvement and toxic effects were similar to each other in 2 groups.Conclusion The life quality of patients with kinds of advanced malignancies may be improved by endostar combined with the related chemotherapy.It is worthy of clinical generalization and further clinical observation.
出处
《实用临床医药杂志》
CAS
2011年第1期39-42,共4页
Journal of Clinical Medicine in Practice
